An appeals panel on Wednesday grappled with the breadth of California negligence law in a case that’s attracted nationwide business and legal interests on both sides, including the U.S. Chamber of Commerce and the American Association for Justice.

More than 24,000 plaintiffs, in lawsuits coordinated in California state courts, alleged that Foster City, California-based Gilead Sciences Inc. delayed the release of an HIV medication that had fewer side effects than its first drug, which caused kidney or bone injuries. Gilead has insisted the new drug was still in development.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]